WS #13332
Investors reject $400B AstraZeneca-Bristol Myers merger, with AZN down 8% and BMY down, signaling deal skepticism.
AZN-BMY merger rejection
Investors reject $400B AstraZeneca-Bristol Myers merger, with AZN down 8% and BMY down, signaling deal skepticism.